A Phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

BACKGROUND: PARP-inhibitors and anti-angiogenics have activity in recurrent ovarian and breast cancer; however, the effect of combined therapy against PARP and angiogenesis in this population has not been reported. We investigated the toxicities and recommended phase 2 dosing (RP2D) of the combinati...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Liu, Joyce F., Tolaney, Sara M., Birrer, Michael, Fleming, Gini F., Buss, Mary K., Dahlberg, Suzanne E., Lee, Hang, Whalen, Christin, Tyburski, Karin, Winer, Eric, Ivy, Percy, Matulonis, Ursula A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3956307/
https://ncbi.nlm.nih.gov/pubmed/23810467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2013.05.020
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky